Vagus nerve stimulation (VNS) is a medical therapy that delivers electrical impulses to the vagus nerve, nudging the brain into calmer, more regulated states. It's been used in clinical medicine since the late 1990s, and in recent years a quieter wave of consumer devices has pushed the concept into gyms, therapy rooms, and lounge rooms across Australia. Understanding what VNS actually does, and where the evidence holds up, is worth your time before you buy a gadget or ask a specialist about an implant.
What the vagus nerve actually is
The vagus nerve is the longest cranial nerve in the human body, running from the brainstem all the way down into the abdomen. It carries signals in both directions: about 80% of its fibres send information up to the brain from the heart, lungs, and gut, and only about 20% carry instructions back down. That ratio matters, because it means the nerve is primarily a reporting line, not a command line. The vagus nerve shapes digestion, heart rate, and immune response, and it sits at the centre of the body's rest-and-digest system. Stimulating it electrically gives clinicians a way to send signals directly into brain regions that are otherwise hard to reach with drugs.
How vagus nerve stimulation works
Clinical VNS uses a small implanted device, roughly the size of a 50-cent coin, placed under the skin near the left collarbone. A thin wire runs from the device up to the left vagus nerve in the neck. The device delivers regular, preset electrical pulses: typically 30 seconds on, 5 minutes off, 24 hours a day. Patients can also swipe a magnet over the device to trigger an extra pulse, which is useful during a seizure or a sudden mood crash.
The pulses travel upward into the brainstem and from there spread into the thalamus, hypothalamus, and cortex. Researchers believe VNS reduces seizure frequency by modulating the excitability of neural circuits, essentially turning down the electrical "noise" that leads to seizures. For depression, the mechanism is less clear, but it appears to increase the availability of norepinephrine and serotonin by activating the locus coeruleus and raphe nuclei. The effect builds slowly, over months, rather than delivering an immediate lift. This is not a quick fix.
What conditions it's used for
The Australian Therapeutic Goods Administration recognises implanted VNS for two primary indications. First, drug-resistant epilepsy. Studies show that roughly 50% of patients with hard-to-treat focal epilepsy see at least a 50% reduction in seizure frequency after 12 months of VNS therapy. That's a meaningful result for people who've exhausted two or more anti-seizure medications. Second, treatment-resistant depression. The TGA approved VNS for this use in adults who haven't responded to 4 or more adequate antidepressant courses. The evidence here is more mixed: a large 2005 randomised controlled trial found modest benefits over sham stimulation, though open-label data over 2 years looks more encouraging.
Researchers are actively investigating VNS for other conditions: post-traumatic stress disorder, inflammatory bowel disease, rheumatoid arthritis, and post-stroke rehabilitation. Some of these trials are genuinely promising. None have yet produced enough evidence to support routine clinical use in Australia.
Non-invasive VNS: the consumer device boom
Transcutaneous VNS (tVNS) skips the surgery entirely. These devices stimulate the auricular branch of the vagus nerve through the outer ear, or through the skin of the neck, using electrodes held against the body. No implant. No anaesthetic. The two most studied devices are gammaCore, which presses against the neck, and auricular tVNS devices that clip to the ear. Both are cleared for use in some jurisdictions for migraine and cluster headache prevention.
The consumer wellness market has taken tVNS further, producing headsets, earbuds, and patches marketed for stress relief, focus, and sleep. The honest position on these is that the evidence is still thin. Lab studies show changes in heart rate variability and measures of autonomic nervous system activity, which is real physiology. But rigorous, double-blinded clinical trials showing sustained, real-world mental health benefits from consumer tVNS devices are scarce. Most studies have small sample sizes, short follow-up periods, and no active control. Buy one with that in mind.
Risks and side effects
Implanted VNS is a surgical procedure and carries surgical risks: infection, device malfunction, and lead displacement. The most common ongoing side effects are hoarseness and throat tingling during each stimulation pulse, which affects roughly 60% of patients. Some people also notice mild shortness of breath or coughing. These effects tend to ease as the device is tuned down. The implant is not compatible with certain types of MRI imaging, which is a practical inconvenience to plan around.
Non-invasive tVNS is generally well tolerated. Skin irritation under the electrode is the most common complaint. There are theoretical concerns about using these devices during pregnancy or in people with active cardiac arrhythmias, so checking with a GP first is sensible.
Who it's right for
Implanted VNS suits a narrow population: people whose epilepsy or depression has not responded to multiple standard treatments and who have been assessed by a neurologist or psychiatrist. It's not a first-line option. The devices cost between $15,000 and $25,000 in Australia, and Medicare rebates apply only to approved indications, so cost is a real barrier for some patients.
Consumer tVNS devices are a different category entirely. They're not harmful for most healthy adults, and the gut-brain axis research that underpins vagal biology is legitimate science. But treating a consumer gadget as equivalent to clinical VNS is a stretch the evidence doesn't yet support. If you're exploring them out of curiosity about autonomic health, that's a reasonable experiment. If you're hoping to replace medication or therapy, talk to your doctor first.
VNS sits at the edge of what modern neuroscience can do: a real, working tool for a subset of patients with serious conditions, and a source of genuine scientific curiosity for everyone else. The gap between those two things is exactly where most of the marketing lives.